CASE REPORT

Hydrocephalus as the presenting symptom of sarcoidosis: A case report and review of literature

Rachel J. Saban¹ | Meaghan M. Berns¹ | Mazen M. Al-Hakim^{1,2} | Gustavo A. Patino^{1,2,3}

¹Oakland University William Beaumont School of Medicine, Rochester, MI

²Department of Neurology, Beaumont Hospital, Royal Oak, MI

³Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI

Correspondence

Gustavo A. Patino, Oakland University William Beaumont School of Medicine, Department of Foundational Medical Studies, Department of Neurology, 586 Pioneer Dr, 422 O'Dowd Hall, Rochester MI 48309. Email: patino@oakland.edu

Abstract

Hydrocephalus is rare in sarcoidosis, especially as the presenting symptom. Neurosarcoidosis as a cause of unexplained communicating hydrocephalus should be considered in cases of abnormal cerebrospinal fluid (CSF) and negative infectious and tumoral studies.

KEYWORDS


granulomatous disease, hydrocephalus, neurosarcoidosis, sarcoidosis

INTRODUCTION 1

Sarcoidosis is a granulomatous disorder of unknown origin that can affect multiple organ systems. Most commonly, it affects the lungs, skin, and lymphatic system. It typically presents in young adults. Central nervous system (CNS) involvement occurs in only 5%-10% of cases and increases

morbidity and mortality significantly.¹ The most common neurologic finding in neurosarcoidosis is cranial neuropathies, predominantly peripheral facial palsy (occurring in 50% of patients), and optic neuritis followed by palate dysfunction, hearing abnormalities, and vertigo.²⁻⁴ Other manifestations include hypothalamic and pituitary abnormalities, chronic aseptic meningitis, mass-lesion effect, and seizures.¹

FIGURE 1 Dilation of third and lateral ventricles with FLAIR sequence (A, B). Enlargement of the third and fourth ventricles with patent cerebral aqueduct on T1 sagittal sequence (C)



This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited

© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.




FIGURE 2 Chest CT demonstrating bilateral enlarged thoracic lymph nodes of 13.0 X 25.3 mm and 9.6 X 14.5 mm consistent with sarcoidosis (A, B). Lymph node biopsy demonstrating granulomatous inflammatory reaction with multinucleate giant cells (black arrowhead) and fibrosis (white arrowhead) (C)

Hydrocephalus occurs in only 6% of cases of neurosarcoidosis, but of all manifestations of CNS involvement, it has been reported to confer the worst long-term prognosis.⁵⁻⁷

In most reported cases of neurosarcoidosis with hydrocephalus, the patient had a previous diagnosis of systemic sarcoidosis. Hydrocephalus as the presenting symptom of sarcoidosis in a previously healthy patient is an atypical presentation that is exceedingly rare and challenging to diagnose.^{1,6} We present the case of a previously healthy 52-year-old woman with significant hydrocephalus of all four ventricles as the presenting manifestation of sarcoidosis.

2 | CASE PRESENTATION

A 53-year-old African-American woman with no past medical history visited the emergency department due to progressive nausea and vomiting. She had a month-long course of fatigue, headaches, intermittent vertigo, tinnitus, and ataxia. Review of systems revealed she had an unintentional weight loss of 30 pounds over the last 4 months. Neurologic examination showed right gaze-evoked nystagmus, postural instability, and an unsteady shuffling gait. Fundoscopic examination showed no papilledema or other abnormalities. Respiratory examination was normal. Her complete blood count and routine biochemistry were normal. C-reactive protein and erythrocyte sedimentation rate (ESR) were within normal limits. Serum level of angiotensin-converting enzyme (ACE) was 51 U/L (normal range: 12-60 U/L). Brain computed tomography (CT) revealed remarkable hydrocephalus with dilation of all four ventricles. Magnetic resonance imaging (MRI) showed patency of the cerebral aqueduct and ruled out cerebral or subarachnoid mass lesions, consistent with communicating hydrocephalus (Figure 1). Lumbar puncture was performed in light of clinical and radiographic findings. Cerebrospinal fluid (CSF) was transparent and showed lymphodominant pleocytosis with increased protein level (104 mg/dL), markedly decreased glucose (21 mg/dL), and normal opening pressure. Chest CT showed bilateral lymphadenopathy, and biopsy revealed noncaseating granulomas admixed with giant cells without evidence of malignancy or infection (Figure 2). A diagnosis of neurosarcoidosis with hydrocephalus was made, and the patient was started on 1 g of intravenous solumedrol for 5 days with a subsequent oral prednisone taper with methotrexate. Three months later, she received a ventricular shunt for persistent severe gait disturbance. She returned to walking independently within one month of the procedure and has since shown marked improvement in all neurologic symptoms.

3 | **DISCUSSION**

Hydrocephalus is a very rare complication of sarcoidosis, especially as the presenting symptom.⁶ We present one such case in this report. To the best of our knowledge, only 21 others exist in the literature, of which we were able to include 19 in this report (Table 1).⁷⁻²² Hydrocephalus typically presents

TABLE 1 H ₃	ydrocephalus as the p	resenting sympt	Hydrocephalus as the presenting symptom in systemic sarcoidosis cases reported in the literature, including the current case	ported in the literature, i	ncluding the current case		
Author	ESR/CRP	Serum ACE	CSF Findings	Diagnosis	Type	Treatment	Outcome
This report	ESR: Normal, CRP: Normal	Normal	Lymphodominant pleocytosis, elevated protein, hypoglycorrhachia	Lymphadenopathy on chest CT	Communicating	Corticosteroids + methotrexate, followed by VP months later	Partial recovery
Brouwer 2009 ⁹		Normal	Lymphodominant pleocytosis, elevated protein	Lymphadenopathy on FDG-PET	Communicating	Corticosteroids	Complete recovery
Muayqil 2006 ¹⁶	ESR: Normal		Lymphodominant pleocytosis	Lymphadenopathy on CXR and chest CT; meningeal and hypothalamic enhancement in brain MRI	Communicating	VP shunt + corticosteroids	Partial recovery
Muniesa 2006 ¹⁷		Elevated	Leukocytic pleocytosis	Cutaneous lesions	Communicating	VP shunt + corticosteroids	Complete recovery
Onoda 2004			Lymphodominant pleocytosis, elevated protein, hypoglycorrhachia	Increased ACE in CSF	Communicating	VP shunt + corticosteroids	Died from nosocomial pneumonia
Sano 2015 ¹⁸			Lymphodominant pleocytosis, protein elevated protein, hypoglycorrhachia, ACE normal	Lymphadenopathy on chest CT; meningeal lesions in basal cisterns	Communicating	VP shunt + corticosteroids +Methotrexate + Infliximab	Partial recovery
Sugiyama 2016 ¹⁹	ESR: Elevated, CRP: Normal	Normal	Leukocytic pleocytosis, elevated protein	Lymphadenopathy on whole body contrast CT and FDG-PET	Communicating	VP shunt + corticosteroids	Partial recovery
Zoja 2012 ²¹				Autopsy	Communicating		Death
Benzagmout 2007 ⁸		Elevated	Elevated opening pressure, lymphodominant pleocytosis, elevated protein, hypoglycorrhachia	Cervical and submandibular lymphadenopathy	Noncommunicating	External Ventricular Drain + Corticosteroids	Partial recovery
Berhouma 2009 ²³				Brain MRI with temporal trapped horn and multiple enhancing lesions in subarachnoid space	Noncommunicating	Right temporal tip lobectomy + corticosteroids	Complete recovery

365

(Continues)

WILEY

Author	ESR/CRP	Serum ACE	CSF Findings	Diagnosis	Type	Treatment	Outcome
Brouwer 2009 ⁹		Normal	Lymphodominant pleocytosis, elevated protein	Lymphadenopathy on FDG-PET	Noncommunicating	Ventriculoscopy assisted fenestration of lateral ventricle cyst	Complete recovery
Chandna 2015 ¹⁰		Normal		Lymphadenopathy on CXR	Noncommunicating	VP shunt + corticosteroids	Death
Chiang 2002 ¹¹		Elevated		Cutaneous lesions	Noncommunicating	VP shunt + corticosteroids	
Hitti 2015 ¹²			Normal	Leptomeningeal enhancement in brain and spine MRI months later	Noncommunicating	VP shunt + corticosteroids +Mycophenolate mofetil	
Kim 2012 ¹³			Leukocytic pleocytosis, elevated protein	Lymphadenopathy on CXR	Noncommunicating	VP shunt + corticosteroids	Complete recovery
Matsuda 2015 ¹⁴		Normal	Lymphodominant pleocytosis, hypoglycorrhachia	Neuroendoscopic biopsy of enhancing ventricular lesions	Noncommunicating	Ventriculostomy, followed by VP shunt + corticosteroids	Complete recovery
McKeever 2019 ¹⁵				Nodular lesions in brain MRI years later	Noncommunicating	Endoscopic third ventriculostomy, years later recurred and required shunt	Complete recovery first episode
Tabuchi 2013 ²⁴	ESR: Elevated, CRP: Normal	Normal	Pleocytosis, elevated protein	Lymphadenopathy on CXR	Noncommunicating	VP shunt + corticosteroids	Partial recovery
Westhout 2008 ²⁰	ESR: Elevated		Elevated protein	Biopsy of temporal lobe lesion	Noncommunicating	VP shunt + corticosteroids	Complete recovery
Y oshitomi 2015 ²⁵	CRP: Elevated		Elevated opening pressure, hypoglycorrhachia	Diffuse leptomeningeal enhancement in brain MRI and mass lesions in third and fourth ventricles	Noncommunicating	Endoscopic fenestration foramen of Magendie, followed by VP shunt + corticosteroids	Complete recovery

TABLE 1 (Continued)

-WILEY

TABLE 2 Differential diagnosis of acquired hydrocephalus in adults

Subarachnoid/Intraventricular Hemorrhage
Trauma
Tumor and metastases (including of the leptomeninges)
Meningitis/encephalitis
Bacterial (including syphilis)
Viral (including EBV and HIV)
Fungal
Infectious etiologies
Tuberculosis
Lyme disease
Toxoplasmosis
Neurocysticercosis
Whipple's disease
Inflammatory etiologies
Sarcoidosis
Systemic lupus erythematosus (SLE)
Behçet's disease
Wegner's granulomatosis

with nonspecific symptoms, and the diagnosis is made based on imaging.⁸ The differential diagnosis is extensive (Table 2) making the correct attribution difficult due to a lack of definitive diagnostic testing for neurosarcoidosis. As such, a high degree of clinical suspicion must be maintained.

Hydrocephalus secondary to sarcoidosis can present as communicating or noncommunicating. The latter scenario is the most common (60% of cases included in this report), and the presence of mass lesions in the CNS can raise the possibility of the diagnosis and even provide a site for biopsy. In the case of communicating hydrocephalus, when the differential diagnosis includes infectious or neoplastic pathologies of the leptomeninges, additional studies (including CSF analysis and chest imaging) usually provide the clues for diagnosis. In 50% of the patients, the diagnosis was suspected when lymphadenopathy was found, most commonly in chest imaging. Among patients with communicating hydrocephalus, this was the most common way to make the diagnosis (63%), including in our patient. In two of those patients, there were also abnormal findings in the contrast MRI (Table 1). In one patient, the diagnosis was made by biopsy of cutaneous lesions, in another, it was suggested by elevated ACE levels in CSF, and in the last case, the patient died suddenly from acute hydrocephalus and the diagnosis was made by pathological examination of the leptomeninges at autopsy.

Serum ACE levels were only reported in half of patients, with only 30% being elevated (25% of communicating and 33% of noncommunicating). All patients with communicating hydrocephalus in whom ESR was reported had normal values, while it was elevated in both patients with

noncommunicating pathology in which it was reported. The most common abnormalities reported in CSF analysis include pleocytosis (100% of communicating and 63% of noncommunicating hydrocephalus) with a lymphocytic predominance in 75% of cases, and elevated protein (71% and 75% respectively). While the number of patients reported is low, the above findings suggest that serum ACE levels have limited sensitivity, but the specificity of the test might still make it valuable. Sarcoidosis should be a diagnostic consideration in patients with hydrocephalus with CSF pleocytosis or elevated protein levels in whom microbiological and cytology studies are negative.

While there has been no controlled trial for medical treatment of neurosarcoidosis, the consensus remains that corticosteroid therapy is first-line. Ventriculoperitoneal (VP) shunt placement should be considered for symptomatic hydrocephalus.⁸ Of the cases reported in the literature, only one case of communicating hydrocephalus in neurosarcoidosis was successfully treated with corticosteroids alone, all other cases required surgical management (VP shunt, ventriculostomy, or ventricle fenestration) which in many cases took place before a definite diagnosis in order to manage the hydrocephalus. In the present case, VP shunt placement was done after three months of persistent and severe gait disturbance despite corticosteroid treatment, with rapid improvement in neurologic symptoms. Obviously, in cases of acute hydrocephalus, ventriculostomy can be life-saving.

While most published reports of hydrocephalus in the context of sarcoidosis suggest a mortality rate as high as 75%, the great majority of those cases happened in patients with widespread disease that had not responded to treatment.^{6,8,26} In the current series of patients presenting with hydrocephalus, the reported mortality is 15%, with one patient dying suddenly from acute hydrocephalus, another from pulmonary embolism, and the last one from nosocomial pneumonia. The rest of the patients in whom outcomes were reported had either partial (35%) or complete (50%) recovery with treatment. Nevertheless, long-term prognosis seems to depend more on the response of the underlying sarcoidosis to immunosuppressant treatment rather than the presence of hydrocephalus.

4 | CONCLUSION

We present a rare case of neurosarcoidosis manifesting as subacute communicating hydrocephalus in a previously healthy patient. Though this pathology may pose a diagnostic challenge, it responds well to treatment and prognosis is favorable.

CONFLICT OF INTEREST

None of the authors have a financial interest in any of the products, devices, or drugs mentioned in this manuscript.

Rachel J. Saban, BS: None declared. Meaghan M. Berns, BA: None declared. Mazen M. Al-Hakim, MD: None declared. Gustavo A. Patino, MD PhD: None declared.

AUTHOR CONTRIBUTIONS

Rachel J. Saban, BS, Meaghan M. Berns, BA, Mazen Al-Hakim, and MD Gustavo Patino, MD PhD: 1) substantially contributed to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafted and revised the article; 3) approved the final version; 4) involved in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

ORCID

368

Rachel J. Saban D https://orcid.org/0000-0002-5846-3441

REFERENCES

- Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. *J Neurol.* 2001;248(5):363-372.
- Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. *Arch Neurol.* 1985;42(9):909-917.
- Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. 2009;80(3):297.
- Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102(7):449-460.
- Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2003;20(2):118-125.
- van Rooijen JM, Mijnhout GS, Aalders TTA, et al. Hydrocephalus, a rare manifestation of sarcoidosis. *Clin Pract*. 2011;1(3):e66.
- Tabushi S, Tetsuji U. Hydrocephalus with panventricular enlargement as the primary manifestation of neurosarcoidosis: a case report. J Med Case Rep. 2013;7:240.
- Benzagmout M, Boujraf S, Gongora-Rivera F, et al. Neurosarcoidosis which manifested as acute hydrocephalus: diagnosis and treatment. *Intern Med.* 2007;46(18):1601-1604.
- Brouwer MC, de Gans J, Willemse RB, et al. Sarcoidosis presenting with hydrocephalus. J Neurol Neurosurg Psychiatry. 2009;80:550-551.
- Chandna A, Todd C, Murphy D, et al. Sarcoidosis presenting with acute hydrocephalus in a New Zealand European female. N Z Med J. 2015;128(1408):110-113.
- Chiang JK, Ortiz-Ferrer LC, Remlinger K, et al. Subcutaneous nodules in a patient with hydrocephalus. *Arch Dermatol.* 2002;138(2):259-264.
- Hitti FL, Kennedy BC, Odia Y, et al. Isolated neurosarcoidosis presenting with recurrent hydrocephalus. *Neuroimmunol Neuroinflamm*. 2015;2:287-290.

- Kim SH, Lee SW, Sung SK, et al. Treatment of hydrocephalus associated with neurosarcoidosis by multiple shunt placement. *J Korean Neurosurg Soc.* 2012;52(3):270-272.
- Matsuda R, Nishimura F, Motoyama Y, et al. A case of intraventricular isolated neurosarcoidosis diagnosed by neuroendoscopic biopsy. *No Shinkei Geka*. 2015;43(3):247-252.
- 15. McKeever A, Cox A, Garnett M, et al. Hydrocephalus as the first presenting symptom of neurosarcoidosis in two patients: a diagnosis more forthcoming in the context of systemic disease. *BMJ Case Rep.* 2019;12(8):e229903.
- Muayqil T, Hussain MS, Saqqur M. A patient with neurosarcoidosis. *Can J Neurol Sci.* 2006;33(1):92-94.
- Muniesa C, Marcoval J, Moreno A, et al. Hydrocephalic neurosarcoidosis diagnosed by cutaneous lesions. *J Am Acad Dermatol*. 2006;55(suppl 5):S125-S126.
- Sano H, Deguchi I, Fukuoka T, et al. Intractable neurosardoicosis effectively treated with infliximab. *Intern Med.* 2016;55(7):811-814.
- Sugiyama A, Kobayashi M, Agatsuma K, et al. Hydrocephalus mimicking idiopathic normal pressure hydrocephalus as the first manifestation of neurosarcoidosis. *Brain Nerve*. 2016;68(12):1477-1482.
- Westhout FD, Linskey ME. Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis. *Surg Neurol*. 2008;69(3):288-292.
- Zoja R, Andreola S, Gentile G, et al. Sudden death from systemic sarcoidosis: a case of legal medicine. *Sarcoidosis Vasc Dif.* 2012;29(1):62-68.
- Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. *Arch Neurol.* 1991;48(8):842-844.
- Berhouma M, Abderrazek K, Krichen W, Jemel H. Apropos of an unusual and menacing presentation of neurosarcoidosis: The space-occupying trapped temporal horn. *Clin Neurol Neurosurg*. 2009;111(2):196–199.
- Tabuchi S, Uno T. Hydrocephalus with panventricular enlargement as the primary manifestation of neurosarcoidosis: a case report. J Med Case Rep. 2013;7:240.
- Yoshitomi M, Uchikado H, Hattori G, Sugita Y, Morioka M. Endoscopic biopsy for the diagnosis of neurosarcoidosis at the fourth ventricle outlet with hydrocephalus. *Surg Neurol Int.* 2015;6:S633–636.
- Stern BJ, Royal W, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group. *JAMA Neurol*. 2018;75(12):1546-1553.

How to cite this article: Saban RJ, Berns MM, Al-Hakim MM, Patino GA. Hydrocephalus as the presenting symptom of sarcoidosis: A case report and review of literature. *Clin Case Rep.* 2020;8:363–368. https://doi.org/10.1002/ccr3.2665